Novel PCSK9 Inhibitors for Treating Cardiovascular Diseases

Ram W. Sabnis

DOI: https://doi.org/10.1021/acsmedchemlett.4c00088

2024-03-08

ACS Medicinal Chemistry Letters

Abstract:Provided herein are novel PCSK9 inhibitors, pharmaceutical compositions, use of such compounds in treating cardiovascular diseases, and processes for preparing such compounds.

chemistry, medicinal

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop new PCSK9 inhibitors for the treatment of cardiovascular diseases. Specifically, the paper focuses on:

1. **Mechanism of action of PCSK9**: PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that plays an important role in cholesterol metabolism. It increases the level of low - density lipoprotein cholesterol (LDL - C) in circulation by enhancing the degradation of low - density lipoprotein receptors (LDL receptors). PCSK9 binds to the LDL receptor on the cell surface and internalizes the complex into the endosome/lysosome compartment. In an acidic environment, it enhances the binding affinity with the LDL receptor, thereby reducing the recycling of the LDL receptor and targeting it for lysosomal degradation.

2. **Limitations of existing treatment regimens**: Currently, the choice of drugs for the treatment of cardiovascular diseases is limited, especially for the inhibition of PCSK9. For example, although statins can reduce LDL - C levels, they actually increase the level of PCSK9 by up - regulating the expression of SREBP - 2 (a transcription factor), which in turn reduces the number of LDL receptors on the cell surface, resulting in high - dose statins failing to achieve the corresponding LDL - C reduction effect.

3. **Development of new PCSK9 inhibitors**: In order to overcome the limitations of existing treatment regimens, this paper describes a series of new PCSK9 inhibitors. These compounds are designed to inhibit PCSK9 more effectively, thereby increasing the level of LDL receptors, further reducing the level of LDL - C in circulation, and ultimately achieving the purpose of treating cardiovascular diseases.

The paper also details the chemical structures, synthesis methods, pharmacological properties, and in - vitro experimental bioactivity data of these new inhibitors. This information provides an important scientific basis for the development of new treatment methods for cardiovascular diseases.